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Summary--The position of the amino acid substitution in the human red cell 
carbonic anhydrase I variant, CA Id Michigan, has been determined by se- 
quence analysis of the altered tryptic peptide. The threonine to lysine 
substitution was found to be located at position 100, and is expressed as 
a 1100 LYS* 
A genetically-determined electrophoretic variant of human red cell 
carbonic anhydrase I (CA I) [also referred to as CA B] was reported from a 
Negro woman and her daughter living in Detroit, Michigan and designated 
CA Id (1). This variant was subsequently characterized chemically by Shows 
(2) who demonstrated that a lysine residue has been substituted for a 
threonine residue in the mutant enzyme. However, the exact position of this 
substitution could not be determined at that time. Recently, the complete 
sequence of human CA I has been determined (3,4,5). It has thus become 
possible to locate the position of the Thr --) Lys change by sequencing the 
peptide isolated from CA Id Michigan which contains the substitution, In 
the present communication, we demonstrate that the threonine residue at 
position 100 has been substituted for lysine in the variant enzyme. 
METHODS 
Both the normal (CA I) and variant (CA Id) enzymes were purified using 
DEAE-cellulose and DEAE-Sephadex column chromatography as previously des- 
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scribed (6). The purity of the isolated components was confirmed using 
starch gel electrophoresis. Following purification, both the normal and 
variant forms of the enzyme were treated, in the presence of 0.05 M N-ethyl 
morpholine, pH 8.2, with a lo-fold excess of citraconic anhydride to block 
all of the lysine residues to tryptic cleavage (7). Excess reagent was 
removed by extensive dialysis against 0.02 M N-ethyl morpholine buffer, 
pH 8.2, after which both samples were treated with 2% trypsfn for two hours 
at 37’. After the tryptic digestion was completed, the volume of each sample 
wae reduced by using a stream of nitrogen gas and mild heat (50-55’); thie 
procedure prevents the precipitation of the large cryptic peptides that are 
produced from the blocking of the lysine residues. The concentrated digerte 
were subsequently fractionated on a Sephadex G-150 column equtllbrated with 
0.05 M N-ethyl morpholine. 
A Beckman automatic sequencer was employed to sequence that region of 
the molecule containing the variant amino mid realdue. A l Urd luIM 
(N,N-dimethylallyamfne) peptide program (Becbn 080570) uaa rued vithout 
alteration except that butanedithiol wae added to the butyl chloride. he 
converted hydantoin derivatives (1 N HCl, 80’ for LO tin) were analyzed 
with standard gas chromatographic procedures (8). Concurrently, a portion 
of the thiazolanone derivative from each requencer step vas converted to 
. 
the constituent amino acid by treating with 5 N HI at 140° for 24 hourr and 
identified on an amino acid analyzer (9). 
RESULTS 
Isolation of 30 mg of CA I and 20 mg of CA Id wao carried out using 
the above methods. Starch gel electrophoreafe revealed no contaminatfon 
of either of the purified forms. Each form was eubrequently treated with 
citraconic anhydride followed by tryptic digestion. Figure 1 ohowe a 
typical elution profile of the lysine-blocked tryptic digertr fractionated 
on Sephadex G-150. 
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Figure 1. Elution profile of a lysine-blocked tryptic digest of CA I. A 
1.5 x 90 cm Sephadex G-150 column equilibrated with 0.05 M N- 
ethyl morpholine was used. Approximately 1.5 ml fractions were 
collected. Both CA I and CA Id showed identical elution patterns. 
Previous experience in this laboratory has shown that the large peak, 
centered at fraction 23 (Fig. l), contains that portion of the molecule 
where, according to Shows (2), the amino acid substitution in CA Id is lo- 
cated. For this reason, the material was further purified using a 0.9 x 60 
cm Sepharose 4B column equilibrated with 0.05 M N-ethyl morpholine, pH 8.2. 
The void volume peptide was partially sequenced to determine the exact nature 
of the presumed amino acid substitution. No contaminating peptides were ob- 
served by this procedure. 
The gas chromstograph and amino acid analyzer results are presented in 
Table I. As can be seen, It is at step 11 that the Thr -4 Lys substitution 
occurs. The presence of lyaine in CA Td was confirmed by amino acid analysis 
of the regenerated amino acid. 
DISCUSSION 
Based on the sequence of both the norms1 and variant peptides, it is 
clear that the Thr -I Lys substitution in the variant molecule occurs at 
sequencer step 11. This site corresponds to residue 100 in the over-all 
sequence of human CA I as independently determined in three laboratories 
(3,4,5). Shows (2) reported that this amino acid substitution did not 
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TABJE I 
Identification of the PTH derivatives from sequence analysis of the normal 
(CA I) and variant (CA Id) lysine-blocked tryptic peptides (Leu-90 to Arg- 
169/173*) isolated by Sepharose 4B column chromatography. 
Position of Derivatives Derivatives 
residue in Sequencer identified by identified with 
CA I sequence** step gas chromatography amino acid analyzer 
CA1 CA Id CA Id 
90 1 I&U T&l LtSl 
91 2 Phe Phe Phe 
92 3 Gln Gln Glx 
93 4 Phe Phe Phe 
94 5 His His His 
95 6 Phe Phe Phe 
96 7 His His Hi.9 
97 8 TrP Trp 
98 9 GUY GUY GUY 
99 10 Ser Ser Ser 
100 11 Thr - A!? Lx!! 
101 12 Asn Asn ASX 
102 13 Glu Glu Glx 
103 14 His His 
104 15 Glu Glu 
105 16 Ser Ser 
106 17 Glu Glu 
107 18 His His 
108 19 Thr 
109 20 Val w 
*This Arg is at position 169 in the sequence of Lin and Deutsch (4), and 
173 in the sequences of Andersson et al. -- (5) and Laurent-Tabusse et al. (3). -- 
**Residue numbers from published sequences of human CA I (3,4,5). 
seem to effect either the CO2 hydrase activity or the esterase activity of 
the mutant enzyme; however, the variant molecule did appear to be more 
thermolabile, and was found to be present in lower amounts, than the normal 
enzyme. In view of these findings, it is of interest that this region of 
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the molecule contains the two histidine residues, 94 and 96, which have been 
implicated as forming two of the three ligands to the single zinc atom at 
the active site (10). It also appears that position 100 is on the surface 
of the molecule. This is based on the three-dimensional structure of the 
other isozyme of human red cell carbonic anhydrase, CA II or CA C (lo), in 
which His-95 (homologous to His-96 of CA I) is located at the C-terminus 
of S-structure 6, and the residue which occurs at position 99 (comparable 
to Thr-100 in CA I) is located on the surface of the molecule. 
ACKNOWLEDGEMENTS 
We are grateful to Mrs. Sharon K. Stroup and Mrs. Ya-Shiou L. Yu for 












Tashian, R.E., Am. J. Human Genetics, 17, 257 (1965). 
shows, T.B., BiGhem. Genetic8, 1, 171 (1967). 
Laurent-Tabusse, G., Giraud, N., and Limozin, N., Biochimie, 54, 
809 (1972). 
Lin, K.-T. I)., and Deutsch, H.F., J. Biol. Chem. (in press). 
Andersson, B., &man, P.O., and Stridx, Biochem. Biophys. Res. - 
Commun., 48, 670 (1972). 
Tani.8, R.J., Tashian, R.E., and Yu, Y.-S.L., J. Biol. %., 245, 
6003 (1970). 
Gibbons, I., and Perham, R.N., Biochem. J., 116, 843 (1970). 
Tanis, R.J., and Tashian, R.E., Biochemistry, 10, 4852 (1971). 
Inglis, A.S., Nicholls, P.W., and Roxburgh, C.M., Au8t. 2. w. g., 
24, 1247 (1971). 
Liljas, A., Kannan, K.K., Bergsten, P.-C., Waara, I., Fridborg, K., 
Strandberg, B., Carlbom, U., Jarup, L., I;dvgren, S., and Petef, M., 
Nature New Biol - - -*y 235, 131 (1972). 
703 
